lenalidomide (Revlimid)
Jump to navigation
Jump to search
Introduction
Trademark: Revlimid, FDA approved 2005
Indications
Contraindications
Dosage
- lenalidomide (25 mg/day for 21 days) & dexamethasone (20 mg on days 1-4 & 12-15 in 28 day cycles
- after stem-cell transplantation: start 5-15 mg/day[3]
Adverse effects
* prophylaxis for deep vein thrombosis
Mechanism of action
Notes
- cost > $160,000/year (2012)[3]
- Manufacturer: Bayer/Onyx
- one of 2 drugs accounting for 26% of total Medicare drug spending but just 1% of claims[9]
More general terms
References
- ↑ Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ UpToDate 14.1 http://www.utdol.com
- ↑ 3.0 3.1 3.2 Palumbo A et al Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma N Engl J Med 2012; 366:1759-1769 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22571200 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1112704
McCarthy PL et al Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma N Engl J Med 2012; 366:1770-1781 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22571201 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1114083
Attal M et al Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma N Engl J Med 2012; 366:1782-1791 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22571202 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1114138
Badros AF Lenalidomide in Myeloma - A High-Maintenance Friend N Engl J Med 2012; 366:1836-1838 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22571206 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1202819 - ↑ Palumbo A et al Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18094721
- ↑ List A, Dewald G, Bennett J, Giagounidis A et al Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021321
- ↑ 6.0 6.1 Celgene Will Discontinue Phase III ORIGIN Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia. July 18, 2013 http://newsroom.celgene.com/press-release/corporate/celgene-will-discontinue-phase-iii-origin-trial-previously-untreated-elderly
Ferrajoli A et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008 Jun 1; 111:5291 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/18334676 <Internet> http://bloodjournal.hematologylibrary.org/content/111/11/5291?ijkey=1f2236d3737b4f81c0700e651c5a72fc5ed0ffa9&keytype2=tf_ipsecsha - ↑ Weber DM, Chen C, Niesvizky R et al Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18032763
- ↑ 8.0 8.1 Deprecated Reference
- ↑ 9.0 9.1 Walker J Small Number of Drugs Drive Big Medicare Bill The Wall Street Journal. April 20, 2015 http://www.msn.com/en-us/money/insurance/small-number-of-drugs-drive-big-medicare-bill/ar-BBiZz23
- ↑ 10.0 10.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, American College of Physicians, Philadelphia 2015, 2018.